{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:47:05Z","timestamp":1770450425839,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"Medical Research Council of South Africa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.euroneuro.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T04:45:24Z","timestamp":1489293924000},"page":"526-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"27","author":[{"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Ahokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Jarema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla S.","family":"Avedisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Vavrusova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Chaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Gruget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Picarel-Blanchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"de Bodinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.02.007_bib1","first-page":"473","article-title":"The diagnosis of and treatment recommendations for anxiety disorders","volume":"111","author":"Allgulander, C., Hackett, D., Salinas, E., 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15\u201322. Baldwin, D.S., Huusom, A.K., Maehlum, E., 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry 189, 264\u2013272. Bandelow","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3274","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"9","author":"de Bodinat","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-155-1-201107050-00006","article-title":"Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study","volume":"155","author":"Dechartres","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/070674370605101304","article-title":"What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension","volume":"51","author":"Fava","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib6","unstructured":"Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338. National Institute of Mental Health, Rockville MD, pp. 217\u2013222."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0b013e32833a86aa","article-title":"Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study","volume":"25","author":"Hale","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/da.21937","article-title":"Generalizability of clinical trial results for generalized anxiety disorder to community samples","volume":"29","author":"Hoertel","year":"2012","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/da.20257","article-title":"Human and economic burden of generalized anxiety disorder","volume":"25","author":"Hoffman","year":"2008","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib11","unstructured":"ICH E9, 1999. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat. Med. 18, pp. 1905\u20131942."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003592","article-title":"Antidepressants for generalized anxiety disorder","author":"Kapczinski","year":"2003","journal-title":"Cochrane. Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.09m05347blu","article-title":"Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline","volume":"71","author":"Kasper","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euroneuro.2014.01.006","article-title":"A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25\u201350mg) in patients with major depressive disorder","volume":"24","author":"Kennedy","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.euroneuro.2015.09.006","article-title":"Sustained efficacy of agomelatine 10mg, 25mg, and 25\u201350mg on depressive symptoms and functional outcomes in patients with major depressive disorder.A placebo-controlled study over 6 months","volume":"26","author":"Kennedy","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.4088\/JCP.v68n1112","article-title":"Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine","volume":"68","author":"Koponen, H., Allgulander, C., Erickson, J., Dunayevich, E., Pritchett, Y., Detke, M.J., Ball, S.G., Russell, J.M., 2007. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion. J. Clin. Psychiatry 9, 100\u2013107. Lemoine","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","article-title":"Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study","volume":"17","author":"Loo","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Millan, M.J., Brocco, M., Gobert, A., Dekeyne, A., 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 177, 448\u2013458. Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib20","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder","volume":"10","author":"Oli\u00e9","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib21","first-page":"1595","article-title":"Agomelatine as monotherapy for major depression: an outpatient, open-label study","volume":"9","author":"Papp, M., Litwa, E., Gruca, P., Mocaer, E., 2006. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 17, 9\u201318. Pecenak","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40263-016-0351-6","article-title":"Characterisation of Agomelatine-Induced Increase in Liver Enzymes: frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients","volume":"30","author":"Perlemuter","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000293525","article-title":"The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment","author":"Rickels","year":"1998","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib24","unstructured":"Servier Laboratories, 2015. Summary of product characteristics: Valdoxan."},{"issue":"Suppl 3","key":"10.1016\/j.euroneuro.2017.02.007_bib25","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2017.02.007_bib26","first-page":"S22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib28","doi-asserted-by":"crossref","unstructured":"Stein, D.J., Hollander, E., 2002. Anxiety Disorders Comorbid with Depression: Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder and Obsessive-Compulsive Disorder. Martin Dunitz, London.","DOI":"10.4324\/9780203215210"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalised anxiety disorder: a 6-month placebo-controlled discontinuation study","volume":"73","author":"Stein","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib32","doi-asserted-by":"crossref","unstructured":"Stein, D.J., Picarel-Blanchot, F., Kennedy, S.H., 2013. Efficacy of the novel antidepressant agomelatine on anxiety symptoms in major depression.","DOI":"10.1002\/hup.2294"},{"key":"10.1016\/j.euroneuro.2017.02.007_bib33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.007_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:52:35Z","timestamp":1568911955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17301785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924977X17301785"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.02.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}